Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

OBJECTIVE: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb/IV and long-term extension studies in adult patients with RA. METHO...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:RMD Open
Autors principals: Cohen, Stanley B, Tanaka, Yoshiya, Mariette, Xavier, Curtis, Jeffrey R, Lee, Eun Bong, Nash, Peter, Winthrop, Kevin L, Charles-Schoeman, Christina, Wang, Lisy, Chen, Connie, Kwok, Kenneth, Biswas, Pinaki, Shapiro, Andrea, Madsen, Ann, Wollenhaupt, Jürgen
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Rheumatoid Arthritis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7722371/
https://ncbi.nlm.nih.gov/pubmed/33127856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2020-001395
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars